Application of HPA in preparation of medicine for treating non-alcoholic fatty liver disease

A fatty liver disease, non-alcoholic technology, applied in the medical field, to achieve the effect of reducing inflammatory response, low price, and reducing economic burden

Active Publication Date: 2021-08-13
YUNNAN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The technical problem to be solved in the present invention is to overcome the existing defects and provide the application of HPA in the preparation of medicines for the treatment of non-alcoholic fatty liver disease, so as to solve the problems raised in the above-mentioned background technology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of HPA in preparation of medicine for treating non-alcoholic fatty liver disease
  • Application of HPA in preparation of medicine for treating non-alcoholic fatty liver disease
  • Application of HPA in preparation of medicine for treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1: Observation and research on rat liver tissue morphology and pathology after PHA treatment of NAFLD rats

[0040] The experimental animals used in the experiment are SD rats. The rats are all male and weigh 180-200g. They are provided by the Experimental Animal Center of Kunming Medical University. The rats are kept in isolation with 12 large cages and 6 small cages. The feeding is conventional Feed, food and water ad libitum;

[0041] The experimental drug p-hydroxyphenylethyl anisate (HPA) was provided by Japan Co., Ltd.; high-density lipoprotein cholesterol (HDL-C), low high-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) kits; interleukin-1α (IL-1α), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α ) kit; total superoxide dismutase (T-SOD), malondialdehyde (MDA) and glutathione peroxidase (GSH-PX) and other related Elisa kits were purchased from ...

Embodiment 2

[0044] Example 2: Study on the improvement of rat liver function and lipid metabolism after HA treatment of NAFLD rats

[0045] The animals and experimental medicines used in this experiment are the same as in Example 1, and related kits such as AST, ALT, HDL-C, LDL-C, TG and TC were purchased from Bio-Swamp Company;

[0046] In the experiment, rat modeling and treatment were identical with the method adopted in Example 1;

[0047] Detect 6 indexes including AST, ALT, HDL-C, LDL-C, TG and TC in rat serum with corresponding kits;

[0048] Compared with the blank control group, the serum AST and ALT, serum and liver HDL-C, LDL-C, TG, and TC in the model group were all significantly increased, and the above indicators in each treatment group were significantly lower than those in the model group (AST: model group 69.28±8.94mmol / L, HPA low-dose treatment group 74.48±9.08mmol / L, HPA high-dose treatment group 76.21±7.14mmol / L, blank control group 69.28±8.94mmol / L; ALT: model group ...

Embodiment 3

[0053] Example 3: Study on Antioxidant Capacity Content in Rat Serum after HPA Treated NAFLD Rats

[0054] The animals and experimental drugs used in this experiment are the same as in Example 1, and related kits such as SOD, MDA, GSH, and CAT were purchased from Nanjing Institute of Bioengineering;

[0055] In the experiment, rat modeling and treatment were identical with the method adopted in Example 1;

[0056] Use corresponding kits to detect the four indicators of rat serum SOD, MDA, GSH, and CAT;

[0057] Compared with the model group, the HPA treatment group has been significantly improved. After the test, the four indicators p<0.05, suggesting that HPA treatment of NAFLD rats can significantly improve the antioxidant capacity of the rats (SOD: model group 263.09±11.87 U / mg, HPA low-dose treatment group 459.98±37.84U / mg, HPA high-dose treatment group 446.26±48.04U / mg, blank control group 407.36±57.61U / mg; MDA: model group 2.26±0.48nmol / mg, HPA Low-dose treatment group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of HPA in preparation of a medicine for treating a non-alcoholic fatty liver disease, and relates to the technical field of medicines. Since the medicine disclosed by the invention serves as a methoxyl derivative, compared with commonly used medicines which are usually clinically used for treating NAFLD at present, on an aspect of treatment of the NAFLD, the medicine has the following advantages of: (1) a curative effect is obvious, especially, liver cells can be protected, and inflammations and an oxidization level can be lightened and lowered; (2) the medicine is high in safety and does not have side or toxic effects; (3) compared with commonly used or reported effective medicines in the current market, the price of the medicine disclosed by the invention is obviously low, and the economic burden of a patient can be lightened; (4) the medicine disclosed by the invention can be combined with other treatment medicines to serve as a compound preparation; and (5) the medicine can directly protect the liver cells when the NAFLD is treated, while the oxidization level in the blood is lowered, an inflammatory reaction can be obviously reduced, and the oxidation resistance of an organism is improved.

Description

technical field [0001] The invention belongs to the field of medical technology, and in particular relates to the application of HPA in the preparation of medicines for treating nonalcoholic fatty liver disease. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) refers to the presence of glycerol in the liver diagnosed by imaging or histology after excluding other liver steatosis diseases, including excessive alcohol consumption, use of steatosis drugs, or genetic diseases. A disease characterized by abnormal accumulation of triesters and inflammatory infiltration. The clinical spectrum of NAFLD is broad, with a spectrum of disease ranging from simple fatty liver without inflammation (NAFL), to nonalcoholic steatohepatitis (NASH), cirrhosis (NAFC) and hepatocellular carcinoma (HCC), with increasing With the improvement of national industrialization and the change of people's lifestyle and dietary structure, the prevalence of NAFLD is increasing, which i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/235A61P1/16
CPCA61K31/235A61P1/16
Inventor 武俊紫陈文慧石安华赵茜马琼
Owner YUNNAN UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap